Navigation Links
Biomatrica Secures Financing of $5 Million
Date:12/5/2012

SAN DIEGO, Dec. 6, 2012 /PRNewswire/ -- Biomatrica, Inc., a leader in ambient temperature biostability technology, today announced the completion of $5 million in private financing. Biomatrica has developed SampleMatrix® technology which has pioneered recent innovations in ambient storage of biological samples, from purified DNA, RNA, and proteins to complex systems such as tissue, cell lines, biopsies and whole blood. The company's products serve a wide range of customers such as those in the molecular diagnostics, forensics, biomedical research (academic, government and industry), and biobanks.

Biomatrica is also funded by Defense Advanced Research Project Agency (DARPA) for basic technology development to solve some of the hardest biostability problems under the Diagnostics on Demand (DxOD) program.  Within this program, Biomatrica is combining their proprietary biostability technology with the most advanced next generation diagnostics technology enabling their applications on a global scale without cold chain requirements.

"With the new funding, we can accelerate the launch of new technologies and products that will stabilize diagnostic assays at ambient temperature," said Judy Muller-Cohn, Ph.D., CEO and co-founder of Biomatrica. "The growth of next generation sample-to-answer diagnostic tests is rapidly emerging, and Biomatrica can offer custom solutions to companies in the molecular diagnostic space."

"Biomatrica's novel chemical stabilization technology offers significant advantages in costs and performance for ambient temperature assays," said Rolf Muller, Ph.D., CSO and co-founder of Biomatrica. "Funds raised in this round of financing will enable us to strengthen our research initiatives, increase manufacturing capabilities and improve company infrastructure."

About Biomatrica®, Inc.
Biomatrica is a leading provider of innovative products for collecting, preserving, analyzing, storing, and shipping biological samples at ambient temperatures. Biomatrica's product range maintains the integrity of DNA, RNA, saliva, blood, tissues and cells both at the point of collection and point of detection. The unique SampleMatrix® technology enables to utilize ambient temperatures for sample collection, preservation and detection resulting in unparalleled advantages in terms of maintaining sample integrity, ease-of-use and reducing per sample costs. The company's products have been adopted and validated at US government forensic agencies, academic research institutions, global biobanks and diagnostic laboratories. Biomatrica's current products include DNAstable®, DNAgard®, RNAstable® and RNAgard®.

More information is available at www.biomatrica.com or call 1-866-379-6879.


'/>"/>
SOURCE Biomatrica
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Systems, Inc. Secures $20 Million Credit Facility
2. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
3. Benvenue Medical Secures $25 Million Series D Financing
4. PLC Systems Secures Additional Financing For US Clinical Trials And General Working Capital
5. Dr. Jills Foot Pads Secures GSA Schedule and Expands to Service VA and Federal Agencies
6. Alexza Secures a $20 Million Committed Equity Financing Facility with Azimuth Opportunity, L.P.
7. BioMotiv Secures $21 million in Initial Funding
8. ROX Medical secures financing and achieves key milestones in providing minimally-invasive approach for treating hypertension
9. Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team
10. Flexion Therapeutics Secures $20 Million in Series B Financing
11. Zafgen Secures $21 Million in Series D Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... the Centers for Disease Control and Prevention (CDC), influenza vaccination should ... helping communities across Massachusetts , Connecticut ... shots through the end of the month. *Some exclusions apply ... ... is by the end of October, according to the Centers for Disease ...
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The International ... promote standards of excellence for the field of eating disorders, announces the opening ... 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
Breaking Medicine News(10 mins):